Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBITDA Margin (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of EBITDA Margin readings, the most recent being 29.34% for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 1216.0% year-over-year to 29.34%, compared with a TTM value of 2.35% through Dec 2025, up 2765.0%, and an annual FY2025 reading of 2.35%, up 2765.0% over the prior year.
  • EBITDA Margin hit 29.34% in Q4 2025 for Apellis Pharmaceuticals, down from 47.08% in the prior quarter.
  • The five-year high for EBITDA Margin was 47.08% in Q3 2025, with the low at 35216.69% in Q2 2021.
  • Median EBITDA Margin over the past 5 years was 127.27% (2023), compared with a mean of 2280.17%.
  • The largest YoY upside for EBITDA Margin was 3425412bps in 2022 against a maximum downside of -47743bps in 2022.
  • Year by year, EBITDA Margin stood at 245.5% in 2021, then crashed by -194bps to 722.94% in 2022, then soared by 91bps to 62.2% in 2023, then surged by 72bps to 17.18% in 2024, then tumbled by -71bps to 29.34% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 29.34%, 47.08%, and 23.34% for Q4 2025, Q3 2025, and Q2 2025 respectively.